Xencor Inc. Stock
Xencor Inc. Stock
The Xencor Inc. price is unchanged compared to yesterday.
With 15 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 22 € there is potential for a 121.11% increase which would mean more than doubling the current price of 9.95 € for Xencor Inc..
Pros and Cons of Xencor Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | 0.000% | 4.737% | 4.188% | -14.957% | -21.654% | -61.731% | -74.223% |
| United Therapeutics | 1.490% | 13.960% | 17.057% | 66.631% | 9.853% | 124.164% | 250.299% |
| Iovance Biotherapeutics Inc. | -1.520% | -21.720% | 59.719% | 6.635% | 46.016% | -42.790% | -88.067% |
| Ligand Pharmaceuticals | -6.250% | 1.667% | 16.561% | 69.444% | 10.241% | 191.773% | 33.091% |
Comments
Xencor (XNCR) had its price target raised by Barclays PLC from $26.00 to $27.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat